RecruitingPhase 2NCT06271837

A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors

A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) as Monotherapy or in Combination With Anti-cancer Agents for the Treatment of Patients With Selected HER2-expressing Tumors (DESTINY PanTumor03)

Sponsor

AstraZeneca

Enrollment

175 participants

Start Date

Feb 18, 2024

Study Type

INTERVENTIONAL

Conditions

Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)

Summary

This is an open-label, multicenter, Phase II study to evaluate the efficacy and safety of trastuzumab deruxtecan as monotherapy or in combination with anti-cancer agents for the treatment in locally advanced, unresectable, or metastatic patients with selected HER2-expressing solid tumors which are not eligible for curative therapy.

Eligibility

Min Age: 18 YearsMax Age: 130 Years

Plain Language Summary

Simplified for easier understanding

This study is testing trastuzumab deruxtecan (T-DXd), a targeted cancer drug, alone or combined with other cancer treatments in people with advanced solid tumors that overexpress a protein called HER2. HER2 is found on the surface of some cancer cells and helps them grow. **You may be eligible if...** - You are 18 or older - You have advanced, unresectable, or metastatic cancer with HER2 expression confirmed by testing - Your cancer can be measured on imaging scans - You are in good overall health (ECOG performance status 0 or 1) **You may NOT be eligible if...** - Your cancer does not express HER2 - Your organ function or blood counts are inadequate - You are not able to use contraception during the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTrastuzumab deruxtecan

Trastuzumab deruxtecan by intravenous infusion

DRUGBevacizumab

Bevacizumab by intravenous infusion

Locations(31)

Research Site

Beijing, China

Research Site

Beijing, China

Research Site

Changchun, China

Research Site

Changsha, China

Research Site

Changzhou, China

Research Site

Chengdu, China

Research Site

Chongqing, China

Research Site

Dongyang, China

Research Site

Guangzhou, China

Research Site

Guangzhou, China

Research Site

Haikou, China

Research Site

Hangzhou, China

Research Site

Hangzhou, China

Research Site

Hangzhou, China

Research Site

Harbin, China

Research Site

Hefei, China

Research Site

Kunming, China

Research Site

Lishui, China

Research Site

Nanchang, China

Research Site

Shandong, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shenyang, China

Research Site

Taiyuan, China

Research Site

Wuhan, China

Research Site

Xi'an, China

Research Site

Xuzhou, China

Research Site

Yinchuan, China

Research Site

Zhengzhou, China

Research Site

Zhengzhou, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06271837